Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
12 Mar 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
ImmunityBio Gets FDA Authorisation to Begin Trial of Novel Covid-19 Vaccine Candidate
31 Oct 2020
Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-based COVID-19 Vaccine
28 Oct 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
23 Sep 2020
Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research
18 Sep 2020
Join Our Newsletter for Free
